‘Polarized Safety Glasses’ are safer than safety glasses for drivers, says Jai Kumar

When it comes to safety glasses there is one clear winner: safety glasses.

Polarised safety glasses are widely used by auto industry and insurance companies to protect drivers against traffic collisions.

They are also widely used to help them spot problems before they happen.

But according to researchers at the National Institute of Standards and Technology (NIST) they have some major drawbacks.

One major drawback of the polarised glasses is that they are expensive and not very useful in most instances.

NIST has developed a prototype for the polarisation glasses, which is now undergoing rigorous testing.

According to the NIST, the polarising glasses are safer and more effective than the conventional safety glasses and have a smaller footprint.

“The polarised safety glass is more cost-effective and smaller, but it also has a smaller user footprint compared to traditional safety glasses,” NIST’s Amitabh Kothari told Quartz.

However, there is another significant disadvantage of the new technology: the glasses are only available for two years and cost about $150.

The cost of the safety glasses can be estimated to be $500, which could mean a big loss to consumers who want to switch to a safer glasses, the researchers said.

The NIST team is looking into how to increase the availability of polarised glass for drivers in the coming years.

“In the coming months, we plan to roll out a series of research and development initiatives aimed at further enhancing the availability and usability of polarising safety glasses across the industry,” the NISTS website said.

“The key objective of these initiatives is to enable consumers to take more effective safety actions while driving,” it said.

When will the coronavirus vaccine become available?

6 November 2018 15:08:18When will the vaccine become widely available?

The answer is not immediately clear.

The first phase of a new generation of vaccines has been under development for nearly a decade.

The government says it will start vaccinating people at least two weeks before the coronivirus pandemic officially starts, and in December, the first batch of vaccines will be given to those who are eligible.

But there is no set date, and the first doses will be distributed on a “waiver basis”, meaning they will only be given if someone can prove they need the vaccine.

In October, the UK announced it was considering extending the first vaccine period to include the second.

The delay has been blamed on the coronovirus, but also on a lack of access to the vaccines.

The UK government also says it has made progress in securing supply.

In May, the United States announced a second dose of the vaccine, with the first scheduled to be made available on October 30.

The US also has a third vaccine in the pipeline, with its first batch due to be given in early November.

The world’s largest vaccine manufacturer, GlaxoSmithKline, is also in talks with the UK and the US.

Meanwhile, some of the world’s biggest vaccine makers are also hoping to secure supply.

Last month, a group of global pharmaceutical companies, including GlaxosmithKline and Sanofi, announced they had agreed to jointly supply two doses of the first-ever vaccine for the pandemic.

However, those talks have now been put on hold. 

The US government has not said when it will officially begin to distribute the vaccines, and it is unclear whether it will do so with or without the UK government’s help.

 What happens next?

There are no guarantees that the pandivirus will be contained.

In a recent report, the UN Office for the Coordination of Humanitarian Affairs (OCHA) warned that the spread of the pandillae virus has now spread to areas in Europe and the Americas, with thousands of deaths reported worldwide.

The pandemic has also triggered an unprecedented rise in COVID-19 cases, with an estimated 4.2 million people now living with the disease.

Many of those cases have been linked to air travel, as the virus spreads by airborne droplets from the same infected air carrier.

The WHO estimates that 1.7 million people worldwide have been infected with the virus, with 1.1 million deaths.